Quantcast

Latest narcolepsy Stories

2009-08-11 15:05:00

PALO ALTO, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the second quarter ended June 30, 2009. Total revenues for the second quarter were $37.3 million, compared to $15.5 million for the quarter ended June 30, 2008. Revenues for the second quarter included a $10.0 million milestone payment from UCB Pharma Limited that was received in July 2008 and recognized as revenue when the last patient completed the second...

2009-06-15 07:00:00

PALO ALTO, Calif., June 15 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals' (Nasdaq: JAZZ) sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia, according to Phase III data presented last week at the 2009 Associated Professional Sleep Societies meeting in Seattle, WA. These data have not been evaluated by the FDA or other regulatory authorities for use of sodium oxybate in the treatment...

fdeaf260be7b1bc3fd204239cec403701
2009-06-10 07:25:00

According to a research abstract that will be presented on Wednesday, June 10, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, getting more high-quality sleep is associated with better academic performance. The positive relationship is especially relevant to performance in math. Results indicate that higher math scores were related to greater sleep quality, less awakenings and increased sleep efficiency. Higher English and history scores were associated...

2009-06-09 15:22:00

PALO ALTO, Calif., June 9 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented this week during the Associated Professional Sleep Societies (APSS) 2009 Annual Meeting in Seattle, Washington and also during the European League Against Rheumatism (EULAR) Congress in Copenhagen, Denmark. Following are the details on each of...

2009-06-01 04:30:00

NUVIGIL Launch Enhanced by Robust Patient Access Programs FRAZER, Pa., June 1 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that NUVIGIL(R) (armodafinil) Tablets [C-IV], a longer-lasting formulation of modafinil, is now available. NUVIGIL is indicated to improve wakefulness throughout the day for the millions of patients who struggle with excessive sleepiness associated with treated obstructive sleep apnea, shift work sleep disorder, also known as shift work...

2009-05-19 07:06:00

Dr. Donnica Moore Translates Sleep Facts from Fiction WASHINGTON, May 19 /PRNewswire/ -- The National Sleep Foundation announced today that, together with sanofi-aventis U.S., it has joined forces with renowned women's health expert Dr. Donnica Moore to debunk common myths and misperceptions about sleep. The partnership is part of an ongoing initiative, Sleeping Smart, which helps educate Americans about the importance of a good night's sleep. Additionally, the campaign motivates sufferers...

134ec9512051fcf031ab90ead6dc78ec1
2009-05-19 06:05:35

Even with regular positive airway pressure, or CPAP treatments, extreme sleepiness during the day remains a constant annoyance for individuals suffering from sleep apnea, Reuters Health reported.  Sleep apnea happens when the supple tissues located in the back of throat collapse momentarily during sleep, resulting in repetitive breathing interruption.  Loud snoring and daytime exhaustion are defining symptoms of the disorder. Studies show that exhaustion during the day can lead to...

2009-05-13 06:30:00

DURHAM, N.C., May 13 /PRNewswire/ -- Addrenex Pharmaceuticals today expanded its pipeline of products aimed at adrenergic regulation with the signing of an agreement to license a new drug for the treatment of narcolepsy, a chronic and debilitating sleep disorder, as well as other neurologic and psychiatric conditions. The agreement to license ADX-N05 gives Addrenex the worldwide rights (excluding East Asia) to develop, manufacture and commercialize the compound from SK Life Science Business...

6ef973f1be2e4542cebde268084bb907
2009-05-04 07:12:14

Ten years ago, Stanford University School of Medicine scientist Emmanuel Mignot, MD, PhD, and his colleagues made headlines when they identified the culprit behind the sleep disorder narcolepsy. Now Mignot and his collaborators have shown for the first time that a specific immune cell is involved in the disorder "” confirming experts' long-held suspicion that narcolepsy is an autoimmune disease. The work, which will be published online May 3 in Nature Genetics, could lead to better...

2009-03-17 13:57:00

Driving hazards caused by sleepiness highlighted on World Sleep Day NEW YORK, March 17 /PRNewswire-USNewswire/ -- Improved diagnosis and treatment of sleep disorders could help to cut fatal or serious road traffic accidents by up to one third, according to the World Association of Sleep Medicine. The announcement has been made on the second annual World Sleep Day, March 20, an international event aimed at raising awareness of the burden and impact of sleep disorders. World Sleep Day is an...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related